ArticleScientific reports2023
Lymphocyte-to-monocyte ratio as a prognostic and potential tumor microenvironment indicator in advanced soft tissue sarcoma treated with first-line doxorubicin therapy.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results.Signal transduction and targeted therapy · 2025Trial
- Optimizing Systemic Therapy for Advanced Sarcomas: Outcomes With Gemcitabine, Docetaxel, Cisplatin, and Everolimus in a Retrospective Single-Center Study.Cancer medicine · 2026Article
- Correlation between novel hematological parameters and assisted pregnancy outcome in frozen-thawed embryo transfer patients.Frontiers in cell and developmental biology · 2026Article
- Clinical and hematological indices as prognosticators in localized solitary fibrous tumors: A retrospective study.Therapeutic advances in medical oncology · 2026Article
- Blood-based biomarkers in soft tissue sarcoma: Implications for immune checkpoint inhibitor therapy.International journal of cancer · 2025Review
- The Lymphocyte-to-Monocyte Ratio (LMR) as a Novel Biomarker for Cervical Cancer Risk Stratification in Conization Patients.Journal of clinical medicine · 2025Article
- Prognostic Value of Inflammatory and Nutritional Indicators in Non-Metastatic Soft Tissue Sarcomas.Journal of inflammation research · 2025Article
- Systemic immune-inflammation index and lymphocyte-to-monocyte ratio predict recurrence after radical surgery for stage I/II endometrial cancer.American journal of cancer research · 2025Article
- A Review on Canine and Human Soft Tissue Sarcomas: New Insights on Prognosis Factors and Treatment Measures.Veterinary sciences · 2024Review
- The lymphocyte-to-monocyte ratio as a significant inflammatory marker associated with survival of patients with metastatic renal cell carcinoma treated using nivolumab plus ipilimumab therapy.International journal of clinical oncology · 2024Article
- Inflammatory markers are associated with infertility prevalence: a cross-sectional analysis of the NHANES 2013-2020.BMC public health · 2024Article
- Association of different inflammatory indices with risk of early natural menopause: a cross-sectional analysis of the NHANES 2013-2018.Frontiers in medicine · 2024Article
- A Longitudinal Dynamic Change in LMR Can Be a Biomarker for Recurrence in Fusobacterium Nucleatum-Positive Colorectal Cancer Patients.Journal of inflammation research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prognostic value of hematologic indices and their association with the tumor microenvironment (TME) remain unclear in advanced soft tissue sarcoma (STS). We aimed to evaluate their prognostic value and correlation with the TME status in advanced STS treated with first-line doxorubicin (DXR) therapy. Clinical data and three hematological indices, including lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio, and neutrophil-to-lymphocyte ratio, were collected from 149 patients with advanced STS. The TME status was pathologically examined by CD3, CD68, and CD20 staining of resected tumor slides. In a multivariate Cox analysis, low LMR and absence of primary tumor resection were independently associated with worse overall survival (OS) (HR 3.93, p = 0.001; HR 1.71, p = 0.03). A prognostic model using these variables predicted OS with greater area under curves than those obtained using Systemic Inflammatory Score and Glasgow Prognostic Score. The LMR significantly correlated with the tumoral CD3/CD68-positive cell ratio in surgical specimens (R = 0.959, p = 0.04). In conclusion, LMR was a prognostic factor in advanced STS treated with first-line DXR therapy. LMR could partially reflect anti-tumor immunity in the TME and have the prognostic value. The potential role of LMR as an indicator of TME status warrants further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.